

Vanda Pharmaceuticals Inc.  
Form 8-K/A  
June 26, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**Amendment No. 1**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 14, 2012**

**VANDA PHARMACEUTICALS INC.**

**(Exact name of Registrant as specified in its charter)**

**Delaware**

**(State or other jurisdiction of incorporation)**

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 8-K/A

**001-34186**  
(Commission File No.)

**03-0491827**  
(IRS Employer Identification No.)

**2200 Pennsylvania Avenue NW**

**Suite 300E**

**Washington, DC 20037**

(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: (202) 734-3400**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On June 18, 2012, Vanda Pharmaceuticals Inc. (the Company) filed a Current Report on Form 8-K (the Form 8-K) announcing that the Company's Board of Directors (the Board) had elected Michael Cola as a director of the Company and a member of the Audit Committee of the Board, effective as of June 14, 2012. The Form 8-K incorrectly stated that Mr. Cola's initial term would expire at the Company's 2015 annual meeting of stockholders. Mr. Cola's initial term will expire at the Company's 2013 annual meeting of stockholders. This Amendment No. 1 amends the Form 8-K solely for purposes of correcting this statement. The remainder of the Form 8-K shall not be effected by the filing of this Amendment No.1.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VANDA PHARMACEUTICALS INC.

By: /s/ JAMES P. KELLY

Name: James P. Kelly

Title: Senior Vice President, Chief Financial Officer,  
Secretary, and Treasurer

Dated: June 25, 2012